Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 4/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12245102 | 0.97 | KCNMA1 (0.60) | KCNMA1AURKARPS6KB1RXFP1DDR2 | |
| Trifluoroacetic Acid SCHEMBL2267687 | 0.95 | AURKA (0.51) | KCNMA1AURKARPS6KB1RXFP1DDR2 | |
| Trifluoroacetic Acid SCHEMBL2267560 | 0.94 | AURKA (0.49) | KCNMA1AURKARPS6KB1RXFP1DDR2 | |
| SCHEMBL12296699 | 0.92 | AURKA (0.54) | KCNMA1AURKARPS6KB1RXFP1DDR2 | |
| Trifluoroacetic Acid SCHEMBL2266473 | 0.92 | AURKA (0.49) | KCNMA1AURKARPS6KB1RXFP1DDR2 | |
| Trifluoroacetic Acid SCHEMBL2268397 | 0.91 | AURKA (0.48) | KCNMA1AURKARPS6KB1RXFP1KDR | |
| Trifluoroacetic Acid SCHEMBL2267329 | 0.90 | AURKA (0.47) | KCNMA1AURKARPS6KB1RXFP1DDR2 | |
| SCHEMBL3817574 | 0.90 | AURKA (0.51) | KCNMA1AURKARPS6KB1RXFP1DDR2 | |
| Trifluoroacetic Acid SCHEMBL2267555 | 0.90 | PARP1 (0.47) | KCNMA1AURKARPS6KB1RXFP1MEN1 | |
| Trifluoroacetic Acid SCHEMBL2269400 | 0.90 | AURKA (0.53) | KCNMA1AURKARPS6KB1LMNAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091920-B1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI SA (FR) | 2014-10-22 | — | — | EP | claimed |
| US-7989439-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI-AVENTIS (FR) | 2011-08-02 | — | — | US | claimed |
| US-20090291984-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2009-11-26 | — | — | US | claimed |
| US-8420824-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-8410286-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI-AVENTIS (FR) | 2013-04-02 | — | — | US | disclosed |
| US-20110237801-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2011-09-29 | — | — | US | disclosed |
| US-20110237641-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2011-09-29 | — | — | US | disclosed |
| US-7989439-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI-AVENTIS (FR) | 2011-08-02 | — | — | US | disclosed |
| US-20090291984-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237801-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | ADORA3, ADORA2B, CYP4B1 | KCNMA1 901/4885AURKA 693/4885RPS6KB1 422/4885 |
| US-20090291984-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | CYP4B1, ADORA1, CYP1B1 | KCNMA1 678/4885AURKA 719/4885RPS6KB1 310/4885 |
| US-20110237641-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | ADORA3, ADORA2B, CYP4B1 | KCNMA1 901/4885AURKA 693/4885RPS6KB1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.